Targeting of uPAR in general and specifically by the clinical candidate huATN-658 has shown significant anticancer effects in a number of preclinical studies22,23; Using huATN-658, we assessed the therapeutic potential for targeting breast cancer and for the first time, breast tumor-induced bone disease. The gene discussed is PLAUR; the disease is breast cancer.